Aripiprazole (Apize, Ariphrenz, Aripiprazole Alkem)
Aripiprazole
Ascend Laboratories (Pty) Ltd
Registration
- Applicant
- Ascend Laboratories (Pty) Ltd
- Certificate holder
- Ascend Laboratories (Pty) Ltd
- Registrations
- 12
- Schedule source
- SAHPRA documentation
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Apize 5 MG ARIPIPRAZOLE | 5 mgTablet | 53075553/2.6.5/0755Approved 21 February 2023 | Registered | S5 | PIPIL |
| Apize 10 MG ARIPIPRAZOLE | 10 mgTablet | 53075653/2.6.5/0756Approved 21 February 2023 | Registered | S5 | PIPIL |
| Apize 15 MG ARIPIPRAZOLE | 15 mgTablet | 53075753/2.6.5/0757Approved 21 February 2023 | Registered | S5 | PIPIL |
| Apize 30 MG ARIPIPRAZOLE | 30 mgTablet | 53075853/2.6.5/0758Approved 21 February 2023 | Registered | S5 | PIPIL |
| Ariphrenz 5 MG ARIPIPRAZOLE | 5 mgTablet | 530759.75553/2.6.5/0759.755Approved 21 February 2023 | Registered | S5 | PIPIL |
| Ariphrenz 10 MG ARIPIPRAZOLE | 10 mgTablet | 530760.75653/2.6.5/0760.756Approved 21 February 2023 | Registered | S5 | PIPIL |
| Ariphrenz 15 MG ARIPIPRAZOLE | 15 mgTablet | 530761.75753/2.6.5/0761.757Approved 21 February 2023 | Registered | S5 | PIPIL |
| Ariphrenz 30 MG ARIPIPRAZOLE | 30 mgTablet | 530762.75853/2.6.5/0762.758Approved 21 February 2023 | Registered | S5 | PIPIL |
| Aripiprazole 5 MG alkem ARIPIPRAZOLE | 5 mgTablet | 530763.75553/2.6.5/0763.755Approved 21 February 2023 | Registered | S5 | PIPIL |
| Aripiprazole 10 MG alkem ARIPIPRAZOLE | 10 mgTablet | 530764.75653/2.6.5/0764.756Approved 21 February 2023 | Registered | S5 | PIPIL |
| Aripiprazole 15 MG alkem ARIPIPRAZOLE | 15 mgTablet | 530765.75753/2.6.5/0765.757Approved 21 February 2023 | Registered | S5 | PIPIL |
| Aripiprazole 30 MG alkem ARIPIPRAZOLE | 30 mgTablet | 530766.75853/2.6.5/0766.758Approved 21 February 2023 | Registered | S5 | PIPIL |
Regulatory status
Where S5 sits on the scale
Prescription-only, with tighter controls on repeats.
Schedule 5 medicines need a prescription, and repeat dispensing is capped at six months in total; the prescriber must state upfront how many times, and at what intervals, it may be repeated. Extra limits apply to some uses: if it is being used for its anxiolytic, antidepressant, tranquillising or analgesic properties, it cannot be prescribed for longer than six months without a further consultation. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S5, read from the product's PI-PIL leaflet.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
Drag to rotate. Structure from PubChem CID 60795.
SAHPRA documents
Schedule Verification
This medication's schedule (S5) has been verified from official SAHPRA documents with 90% confidence.
These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.